Every 5 minutes, a woman in the United States receives a uterine cancer diagnosis, a stark reality reflected in the over 66,000 new cases estimated for 2023 that underscores the critical need for awareness and understanding of this increasingly common disease.
Key Takeaways
- In 2023, approximately 66,470 new cases of uterine corpus cancer were estimated to be diagnosed among women in the United States
- The lifetime risk of developing uterine corpus cancer for a woman in the US is about 3.1% or 1 in 32
- Uterine cancer accounts for about 6% of all new cancer cases in US women, ranking as the fourth most common cancer
- Obesity increases endometrial cancer risk by 2-4 times compared to normal weight women
- Type 2 diabetes mellitus is associated with a 2.8-fold increased risk of endometrial cancer
- Postmenopausal estrogen-only hormone therapy raises risk by 2-10 times depending on duration
- Vaginal abnormal bleeding is the presenting symptom in 90% of postmenopausal endometrial cancer cases
- Endometrial biopsy detects 90-95% of endometrial cancers
- Transvaginal ultrasound sensitivity for detecting endometrial cancer is 96% when endometrial thickness >4mm in postmenopausal women
- Hysterectomy is the primary treatment for 95% of stage I-II uterine cancers
- 5-year survival for localized uterine corpus cancer is 94.7% in the US
- Adjuvant radiation reduces locoregional recurrence by 50% in intermediate-risk stage I
- In 2023, uterine corpus cancer caused 12,160 deaths in the US
- Mortality rate for uterine corpus cancer is 4.9 per 100,000 women per year (2015-2019)
- Black women face 2.1 times higher mortality rate (11.6 vs 5.5 per 100,000)
Uterine cancer cases are rising globally, especially in Black women who face significantly higher risks.
Epidemiology
1In 2023, approximately 66,470 new cases of uterine corpus cancer were estimated to be diagnosed among women in the United States
Verified2The lifetime risk of developing uterine corpus cancer for a woman in the US is about 3.1% or 1 in 32
Verified3Uterine cancer accounts for about 6% of all new cancer cases in US women, ranking as the fourth most common cancer
Verified4From 2015–2019, the incidence rate of uterine corpus cancer was 28.7 per 100,000 women per year based on 62,339 cases
Directional5Uterine corpus cancer incidence rates have been rising by 0.6% annually over the past decade in the US
Single source6Black women have a 63% higher incidence rate of uterine corpus cancer compared to White women (32.9 vs 20.2 per 100,000)
Verified7Globally, there were an estimated 417,367 new cases of uterine cancer in 2020
Verified8Uterine cancer is the 6th most common female cancer worldwide, with higher rates in high-income countries
Verified9In Europe, the age-standardized incidence rate for uterine corpus cancer is 20.3 per 100,000 women
Directional10Among US women aged 45-54, uterine cancer incidence has increased by 2.2% per year from 2007-2016
Single source11Prevalence of uterine cancer survivors in the US is about 873,649 as of 2022
Verified12In China, uterine corpus cancer incidence rose from 6.8 to 12.6 per 100,000 between 2008-2016
Verified13Hispanic women in the US have seen a 2.5% annual increase in uterine cancer rates over the last decade
Verified14Uterine cancer represents 3.4% of all new cancer cases in Canada in 2022
Directional15In Australia, 2,313 new cases of uterine cancer were diagnosed in 2022
Single source16Age-specific incidence peaks at 70-74 years for uterine corpus cancer in the US at 192.6 per 100,000
Verified17In Japan, uterine corpus cancer cases increased by 4.2% annually from 1993-2015
Verified18UK incidence rate for uterine cancer is 27 per 100,000 women
Verified19In low-income countries, uterine cancer incidence is lower at 5.9 per 100,000 vs 24.3 in high-income
Directional20US women under 50 now account for 14% of new uterine cancer cases, up from previous decades
Single source21In India, age-adjusted incidence of uterine cancer is 2.4 per 100,000 women
Verified22Brazilian national incidence of uterine cancer was 10.6 per 100,000 in 2018
Verified23In South Korea, uterine corpus cancer incidence reached 17.7 per 100,000 in 2017
Verified24French women have an incidence rate of 21.8 per 100,000 for uterine cancer
Directional25In the US, endometrioid type accounts for 80-90% of uterine corpus cancers histologically
Single source26Global prevalence of uterine cancer is estimated at 1.9 million women living with the disease in 2020
Verified27Italian incidence rate for uterine cancer is 18.5 per 100,000 women
Verified28In Sweden, uterine cancer incidence is 31 per 100,000, one of the highest in Europe
Verified29US Asian/Pacific Islander women have the lowest incidence at 15.3 per 100,000
Directional30In 2022, projected 65,950 new US cases of endometrial cancer specifically
Single sourceEpidemiology Interpretation
Uterine cancer is a stealthy, rising foe—now the fourth most common cancer in American women—that disproportionately strikes Black women and increasingly targets younger women, while the disease's global shadow shows that wealthier nations paradoxically bear the heaviest burden.
Mortality and Prognosis
1In 2023, uterine corpus cancer caused 12,160 deaths in the US
Verified2Mortality rate for uterine corpus cancer is 4.9 per 100,000 women per year (2015-2019)
Verified3Black women face 2.1 times higher mortality rate (11.6 vs 5.5 per 100,000)
Verified4Globally, 97,370 deaths from uterine cancer occurred in 2020
Directional5Mortality rates have increased 1.2% annually since 2009 in the US
Single source6Serous and clear cell histologies have 5-year survival <50% vs 90% endometrioid
Verified7Stage IV disease mortality approaches 80% within 5 years
Verified8Recurrence rate for stage I high-risk is 15-20% within 3 years
Verified9Median overall survival for recurrent disease is 12-24 months
Directional10Lymphovascular invasion increases mortality risk by 3-fold in early stage
Single source11Distant metastasis 5-year survival is 18.7%
Verified12Age >60 at diagnosis halves 5-year survival odds
Verified13High-grade tumors (grade 3) have 50% increased mortality hazard
Verified14Positive peritoneal cytology worsens prognosis with 20% lower survival
Directional15p53 mutation status predicts poor prognosis with HR 2.5 for recurrence
Single source16MSI-high status improves prognosis with 20% better survival in stage II-III
Verified17Deep myometrial invasion (>50%) doubles mortality risk in stage I
Verified1830-day postoperative mortality after hysterectomy is 0.5-1%
Verified19Cervix involvement increases recurrence risk by 2-fold
Directional20Obesity BMI>40 raises postoperative mortality by 2.5 times
Single source21Adnexal involvement portends 40% 5-year mortality in early stage
Verified22POLE ultramutated subtype has excellent prognosis >95% 5-year survival
Verified23Global age-standardized mortality rate is 2.1 per 100,000 women
Verified24Comorbidity index >2 increases 5-year mortality by 30%
Directional25Vaginal recurrence mortality is 50% if untreated
Single source26TCGA classification: serous-like poorest prognosis with median OS 23 months
VerifiedMortality and Prognosis Interpretation
While the average odds are grim, this disease plays a cruelly biased game, disproportionately claiming Black women and those with aggressive subtypes, yet it also holds surprising cards, where molecular quirks can offer a reprieve or seal a fate.
Risk Factors
1Obesity increases endometrial cancer risk by 2-4 times compared to normal weight women
Verified2Type 2 diabetes mellitus is associated with a 2.8-fold increased risk of endometrial cancer
Verified3Postmenopausal estrogen-only hormone therapy raises risk by 2-10 times depending on duration
Verified4Nulliparity (never giving birth) confers a 2-fold higher risk of endometrial cancer
Directional5Each 5-unit increase in BMI above 25 increases endometrial cancer risk by 60%
Single source6Polycystic ovary syndrome (PCOS) is linked to a 3.11 relative risk for endometrial cancer
Verified7Late menopause (after age 52) increases risk by 1.5-2 times
Verified8Tamoxifen use for breast cancer raises endometrial cancer risk by 2-7 fold
Verified9Hereditary nonpolyposis colorectal cancer (HNPCC/Lynch syndrome) carries 40-60% lifetime risk of endometrial cancer
Directional10First-degree family history of endometrial cancer doubles the risk
Single source11Unopposed estrogen exposure for 10+ years increases risk 10-fold
Verified12Smoking reduces endometrial cancer risk by 20-30% in postmenopausal women
Verified13Physical activity reduces risk by 20-40% with high vs low activity levels
Verified14Oral contraceptive use for 5+ years lowers risk by 50%
Directional15Hypertension is associated with 1.5-fold increased risk of endometrial cancer
Single source16BRCA1 mutation carriers have a 19-66% lifetime risk of endometrial cancer in some studies
Verified17Early age at menarche (<12 years) increases risk by 1.5 times
Verified18Coffee consumption of 4+ cups/day reduces risk by 25%
Verified19Statin use is linked to 20-30% risk reduction in meta-analyses
Directional20Endometrial hyperplasia without atypia progresses to cancer in 1-3% of cases
Single source21Atypical endometrial hyperplasia has 25-40% progression rate to endometrial cancer
Verified22Aspirin use reduces endometrial cancer risk by 17% in regular users
Verified23Metabolic syndrome components increase risk synergistically up to 3-fold
Verified24Multiparity (3+ births) reduces risk by 30-50%
Directional25Vitamin D deficiency is associated with 2-fold higher risk in some cohorts
Single source2680% of endometrial cancers are linked to excess estrogen exposure
Verified27Breastfeeding reduces risk by 10-20% per year of duration
Verified28Alcohol consumption shows inverse association, reducing risk by 10-15%
VerifiedRisk Factors Interpretation
A woman’s risk for endometrial cancer appears to be a grim accounting of her life, where the protective credits of pregnancy, exercise, and coffee can seldom fully offset the heavy debits of obesity, unopposed estrogen, and family history.
Symptoms and Diagnosis
1Vaginal abnormal bleeding is the presenting symptom in 90% of postmenopausal endometrial cancer cases
Verified2Endometrial biopsy detects 90-95% of endometrial cancers
Verified3Transvaginal ultrasound sensitivity for detecting endometrial cancer is 96% when endometrial thickness >4mm in postmenopausal women
Verified475-80% of uterine cancers are diagnosed at stage I
Directional5Pelvic pain occurs in 20-25% of advanced uterine cancer cases
Single source6CA-125 is elevated in 25% of early-stage and 80% of advanced endometrial cancers
Verified7Hysteroscopy allows visualization and biopsy with 98% sensitivity for focal lesions
Verified8Postmenopausal bleeding prompts evaluation in 10% of cases leading to cancer diagnosis
Verified9MRI staging accuracy for deep myometrial invasion is 85-92%
Directional10Weight loss occurs in 10-15% of symptomatic endometrial cancer patients
Single source11Pipelle endometrial sampling has 91-99% sensitivity for detecting cancer
Verified12PET/CT detects lymph node metastases with 82% sensitivity in high-risk cases
Verified13Discharge or spotting reported in 15-20% pre-diagnosis
Verified14Endometrial thickness >5mm in premenopausal women warrants biopsy in 20% abnormal cases
Directional15CT scan detects extrauterine disease in 70-80% accuracy for staging
Single source16Fatigue present in 30% of newly diagnosed uterine cancer patients
Verified17HE4 biomarker outperforms CA-125 in early detection with AUC 0.93
Verified185% of premenopausal abnormal bleeding leads to endometrial cancer finding
Verified19Sentinel lymph node mapping detects metastases with 90% accuracy in early stage
Directional20Pelvic ultrasound first-line for postmenopausal bleeding with 96% NPV if thin stripe
Single source21Lower abdominal pain in 5-10% early stage, rising to 40% in advanced
Verified22Dilation and curettage diagnostic yield 60% for malignancy in high suspicion
Verified23ROMA index predicts recurrence with 75% sensitivity post-treatment
Verified24Urinary symptoms like hematuria in 5% due to advanced local invasion
Directional2590% of stage I cancers diagnosed via office biopsy without anesthesia
Single source26Chest X-ray abnormal in 15% of stage IV uterine cancer at diagnosis
Verified27Mean age at diagnosis for endometrioid type is 63 years
Verified2870% of uterine cancers are low-grade endometrioid at diagnosis
VerifiedSymptoms and Diagnosis Interpretation
While the numbers paint a hopeful picture of early detection through simple measures like investigating postmenopausal bleeding, they soberly remind us that when symptoms like pelvic pain or weight loss join the party, the disease has often already made itself far too comfortable.
Treatment and Survival
1Hysterectomy is the primary treatment for 95% of stage I-II uterine cancers
Verified25-year survival for localized uterine corpus cancer is 94.7% in the US
Verified3Adjuvant radiation reduces locoregional recurrence by 50% in intermediate-risk stage I
Verified4Overall 5-year relative survival for uterine corpus cancer is 84.5%
Directional5Chemotherapy with carboplatin-paclitaxel improves PFS by 10 months in advanced disease
Single source6Stage III 5-year survival is 73.7%, dropping to 20.1% for stage IV
Verified7Minimally invasive surgery (laparoscopic) has 10% lower complication rate vs open
Verified8Hormone therapy effective in 20-30% low-grade advanced endometrioid cancers
Verified9PORTEC-2 trial showed vaginal brachytherapy equivalent to pelvic RT with less toxicity
Directional10Immunotherapy with pembrolizumab yields 48% response rate in MSI-high tumors
Single source11GOG-249 trial: 3-year RFS 84% with brachytherapy vs 77% pelvic RT
Verified12Robotic hysterectomy shortens hospital stay by 2-3 days vs abdominal
Verified13PARP inhibitors show promise in 20% HRD-positive uterine cancers
Verified14Lymphadenectomy in low-risk stage I does not improve survival per GOG-99
Directional1510-year survival for grade 1 stage IA is 98%
Single source16Trastuzumab effective in 30% HER2-positive uterine serous carcinomas
Verified17Dose-dense paclitaxel boosts OS by 12 months in high-risk advanced disease
Verified18Observation alone safe for low-risk stage I with 95% 5-year RFS
Verified19Bevacizumab adds 4 months PFS in recurrent disease per GOG-218
Directional20Sentinel node biopsy reduces lymphedema risk by 70% vs full lymphadenectomy
Single source2190% of stage I patients cured with surgery alone
Verified22Lenvatinib + pembrolizumab ORR 38% in non-MSI-high advanced disease
Verified23Adjuvant chemotherapy improves 5-year OS by 10-15% in stage III
Verified24Vaginal brachytherapy reduces vaginal recurrence to 2% vs 6% no RT
Directional25Median survival for stage IVB is 31 months with modern chemo-immuno
Single source26Black women have 40% lower 5-year survival (63.3% vs 84.9%) despite similar stage
Verified2715-year survival for low-risk early stage exceeds 90%
Verified28Dostarlimab achieves 42% response in dMMR recurrent endometrial cancer
Verified29Combined chemo-RT improves OS by 15% in high-intermediate risk stage I-II
DirectionalTreatment and Survival Interpretation
The story here is one of remarkable success when we catch it early, but a stark and urgent reminder that our best tools become far less effective if we wait too long, and tragically, not everyone gets equal access to the fight.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2SEERseer.cancer.govVisit source
- Reference 3CANCERcancer.govVisit source
- Reference 4GCOgco.iarc.who.intVisit source
- Reference 5WHOwho.intVisit source
- Reference 6ECISecis.jrc.ec.europa.euVisit source
- Reference 7PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 8ACSJOURNALSacsjournals.onlinelibrary.wiley.comVisit source
- Reference 9CANCERcancer.caVisit source
- Reference 10AIHWaihw.gov.auVisit source
- Reference 11CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 12AIOMaiom.itVisit source
- Reference 13NCBIncbi.nlm.nih.govVisit source
- Reference 14ACOGacog.orgVisit source
- Reference 15NCCNnccn.orgVisit source